KeyNeurotek Pharma Receives OD Designation of its lead compound KN38-7271 for the treatment of moderate and severe closed traumatic brain injury

KeyNeurotek Pharmaceuticals AG, a biotechnology company focused on the development and marketing of drugs against autoimmune diseases and degenerative disorders of the central nervous system (CNS), today announced that the Committee for Orphan Medicinal Products (COMP) of the London-based European Medicines Agency (EMEA) has approved KN38-7271 as an Orphan Medicinal Product for the orphan indication moderate and severe closed traumatic brain injury (TBI).

The details can be read here.